← Back to Search

Implantable Device

Study of the Beacon Aqueous Microshunt in Patients With Refractory Glaucoma (Beacon Trial)

N/A
Waitlist Available
Research Sponsored by MicroOptx
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a small device called the Beacon Aqueous Microshunt in patients with glaucoma that doesn't respond to usual treatments. The device helps drain excess fluid from the eye to reduce pressure and prevent vision damage. The Beacon Aqueous Microshunt is an 8.5 mm glaucoma drainage device designed to reduce eye pressure in glaucoma patients.

Eligible Conditions
  • Glaucoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Effectiveness via Intraocular Pressure Reduction
Safety via Serious and Adverse Event Reporting
Secondary study objectives
Kaplan-Meier Analysis of Failure

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Beacon Aqueous MicroshuntExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

MicroOptxLead Sponsor
2 Previous Clinical Trials
18 Total Patients Enrolled
2 Trials studying Glaucoma
18 Patients Enrolled for Glaucoma
~2 spots leftby Dec 2025